Triveni Bio Doses First Healthy Volunteers with Next-Generation Bispecific Antibody TRIV-573 Targeting Kallikreins 5 & 7 and Interleukin 13 in Phase 1 Clinical Trial

— Dual mechanism uniquely combines barrier repair (KLK5/7) and established anti-inflammatory blockade (IL-13) to bring a first-in-class therapeutic to patients in atopic dermatitis — — Phase 2 patient proof-of-concept study in moderate-to-severe atopic dermatitis expected to initiate later this year — WATERTOWN, MA – May 18, 2026 – Triveni Bio, Inc., a clinical-stage biotechnology company focused on […] The post Triveni Bio Doses First Healthy Volunteers with Next-Generation Bispecific Antibody TRIV-573 Targeting Kallikreins 5 & 7 and Interleukin 13 in Phase 1 Clinical Trial appeared first on